Literature DB >> 16684806

Prevalence of diarrhea at a university hospital and association with modifiable risk factors.

Kevin W Garey1, Gail Graham, Laura Gerard, Thanh Dao, Zhi Dong Jiang, Margaret Price, Herbert L Dupont.   

Abstract

OBJECTIVE: To assess the prevalence of diarrhea at a university-affiliated medical center and the presence of modifiable risk factors.
METHODS: A point prevalence survey was conducted. All patients hospitalized for more than 24 hours were asked if they were experiencing diarrhea. Stools of patients not previously tested were assessed for Clostridium difficile (CD) toxins A and B. Univariate analysis and multivariate logistic regression analyses were used to identify modifiable variables associated with diarrhea (significance defined as p < 0.05).
RESULTS: Four hundred eighty-five hospitalized patients were interviewed, of whom 60 (12.4%) reported 2 or more loose, unformed stools in the last 24 hours. Six of 81 (7.4%) patients tested positive for CD toxin. Three (50%) of the CD toxin-positive patients had not previously been tested during the current admission. Patients with diarrhea were more likely to have tested CD toxin-positive (OR 10.6; p = 0.01), received antibiotics (OR 1.79; p = 0.04), or been hospitalized for a longer period of time (p = 0.04).
CONCLUSIONS: Diarrhea was prevalent in 12.4% of hospitalized patients at a large university hospital at one point in time. Patients with diarrhea were more likely to have CD infection, receive antibiotics, or experience a longer hospitalization. Half of the CD diarrhea cases occurring in the hospital had been previously unidentified. Hospitalized patients should be evaluated for diarrhea on an ongoing basis with appropriate interventions instituted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684806     DOI: 10.1345/aph.1H028

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

Review 1.  Rapid detection of Clostridium difficile toxins and laboratory diagnosis of Clostridium difficile infections.

Authors:  Shuyi Chen; Huawei Gu; Chunli Sun; Haiying Wang; Jufang Wang
Journal:  Infection       Date:  2016-09-06       Impact factor: 3.553

Review 2.  Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile.

Authors:  Christopher R Polage; Jay V Solnick; Stuart H Cohen
Journal:  Clin Infect Dis       Date:  2012-06-14       Impact factor: 9.079

3.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

4.  Outcomes in patients tested for Clostridium difficile toxins.

Authors:  Christopher R Polage; David L Chin; Jhansi L Leslie; Jevon Tang; Stuart H Cohen; Jay V Solnick
Journal:  Diagn Microbiol Infect Dis       Date:  2012-09-23       Impact factor: 2.803

5.  Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital.

Authors:  Miguel Salazar; Kevin W Garey; Zhi-Dong Jiang; Thanh Dao-Tran; Herbert DuPont
Journal:  Pharm World Sci       Date:  2009-08-06

6.  Assessment of the incidence and etiology of nosocomial diarrhea in a medical ward in Iraq.

Authors:  Ammar Jabbar Hamad; Aseel Jassim Albdairi; Samer Nema Yassen Alkemawy; Safaa Ali Khudair; Noor Rafea Abdulhadi
Journal:  J Med Life       Date:  2022-01

7.  Laxative Use Does Not Preclude Diagnosis or Reduce Disease Severity in Clostridiodes difficile Infection.

Authors:  Nicole C White; Rafael Mendo-Lopez; Konstantinos Papamichael; Christine A Cuddemi; Caitlin Barrett; Kaitlyn Daugherty; Nira Pollock; Ciaran P Kelly; Carolyn D Alonso
Journal:  Clin Infect Dis       Date:  2020-09-12       Impact factor: 9.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.